

REFERENCES: (Sources: Pubmed/literature search, ASCO, www.cancer.org, UptoDate.com)

N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Maxson JE¹, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW.

Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Piazza R¹, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boulwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistrini V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C.

Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Vardiman JW¹, Thiele J, Arber DA, Bruning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD.

Blood. 2001 Aug 15;98(4):1182-7.

T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10.

Liu H¹, Ye H, Dogan A, Ranaldi R, Hamoudi RA, Bearzi I, Isaacson PG, Du MQ.

Blood. 2003 Apr 1;101(7):2547-50. Epub 2002 Nov 27.

High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma.

Ye H¹, Liu H, Raderer M, Chott A, Ruskone-Fourmesttraux A, Wotherspoon A, Dyer MJ, Chuang SS, Dogan A, Isaacson PG, Du MQ.

J Clin Oncol. 2000 Nov 1;18(21):3707-21.

Molecular biology of Burkitt's lymphoma.

Hecht JL¹, Aster JC.

Nature. 1982 Jul 29;298(5873):474-6.

Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.

Lenoir GM, Preud'homme JL, Bernheim A, Berger R.

J Clin Oncol. 1999 Aug;17(8):2461-70.

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.

Thomas DA¹, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H.

Cancer. 2006 Apr 1;106(7):1569-80.

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Thomas DA¹, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H.

Ann Hematol. 2014 Dec;93(12):2001-10. doi: 10.1007/s00277-014-2142-9. Epub 2014 Jul 2.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Lucena-Araujo AR¹, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattoni CS, Lima AS, Ruiz-Argüelles G, Undurraga MS, Martinez L, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Leuk Res. 2015 Jul 2. pii: S0145-2126(15)00188-5. doi: 10.1016/j.leukres.2015.05.016. [Epub ahead of print]

Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.

Lou Y¹, Ma Y¹, Suo S¹, Ni W¹, Wang Y¹, Pan H¹, Tong H¹, Qian W¹, Meng H¹, Mai W¹, Huang J¹, Yu W¹, Wei J¹, Mao L¹, Jin J².

Expert Opin Investig Drugs. 2014 Jul;23(7):943-54. doi: 10.1517/13543784.2014.911839. Epub 2014 Apr 21.

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.

Pemmaraju N¹, Kantarjian H, Andreeff M, Cortes J, Ravandi F.

Cancer. 2011 Aug 1;117(15):3293-304. doi: 10.1002/cncr.25908. Epub 2011 Feb 11.

FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

Pemmaraju N¹, Kantarjian H, Ravandi F, Cortes J.

Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Frankel AE¹, Woo JH², Ahn C¹, Pemmaraju N³, Medeiros BC⁴, Carraway HE⁵, Frankfurt O⁶, Forman SJ⁷, Yang XA⁸, Konopleva M³, Garnache-Ottou F⁹, Angelot-Delettire F⁹, Brooks C¹⁰, Szarek M¹⁰, Rowinsky E¹⁰

Am J Hematol. 2013 Dec;88(12):1055-61. doi: 10.1002/ajh.23567. Epub 2013 Sep 30.

TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.

Alayed K¹, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD.

2014 ASCO Annual Meeting

Abstract Number: 7118, J Clin Oncol 32:5s, 2014 (suppl; abstr 7118)

Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes **Author(s): Naveen Pemmaraju, Deborah A. Thomas, Hagop M. Kantarjian, Jorge E. Cortes, Joseph Khoury, John T Manning, L Jeffrey Medeiros, Susan Mary O'Brien, Naval Guastad Daver, Sherry Pierce, Guillermo Garcia-Manero, Elias Jabbour, Nitin Jain, Muzaffar H. Qazilbash, Stefan Faderl, Arthur E. Frankel, Marina Konopleva; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson, Houston, TX; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; Scott & White Cancer Research Institute, Temple, TX**

Front Oncol. 2014 Oct 29;4:297. doi: 10.3389/fonc.2014.00297. eCollection 2014.

A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine.

Sasaki K¹, Pemmaraju N¹, Westin JR², Wang WL³, Khoury JD⁴, Podoloff DA⁵, Moon B⁶, Daver N¹, Borthakur G¹.

Blood. 2012 Sep 27;120(13):2700-3. Epub 2012 Aug 9.

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Haroche J¹, Charlotte E, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, Canioni D, Galmiche L, Rose C, Schmalzing M, Croockewit S, Kambouchner M, Copin MC, Fraitag S, Sahm F, Brousse N, Amoura Z, Donadieu J, Emile JF.
Blood. 2014 Aug 14;124(7):1119-26. doi: 10.1182/blood-2013-12-543793. Epub 2014 Jun 3.

Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.

Hervier B¹, Haroche J¹, Arnaud L¹, Charlotte F², Donadieu J³, Néel A⁴, Lifermann F⁵, Villabona C⁶, Graffin B⁷, Hermine O⁸, Rigolet A⁹, Roubille C¹⁰, Hachulla E¹¹, Carmoi T¹², Bézier M¹³, Meignin V¹³, Conrad M¹⁴, Marie L¹⁵, Kostrzewa E¹⁶, Michot JM¹⁷, Barete S¹⁸, Taly V¹⁹, Cury K¹⁸, Emile JF²⁰, Amoura Z¹; French Histiocytoses Study Group.

Blood. 1997 Mar 15;89(6):2079-88.

International scoring system for evaluating prognosis in myelodysplastic syndromes.

Greenberg P¹, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohgashiki K, Toyama K, Aul C, Mufti G, Bennett J.

J Clin Oncol. 2000 Feb;18(3):547-61.

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

Kantarjian HM¹, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ.

Cancer. 2009 May 15;115(10):2147-54. doi: 10.1002/cncr.24266.

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.

Garg R¹, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S.

Blood. 2015 Aug 6;126(6):721-32. doi: 10.1182/blood-2015-01-553974. Epub 2015 May 22.

How I treat Waldenström macroglobulinemia.

Treon SP¹.

N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Treon SP¹, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.

Blood. 2015 Jul 23;126(4):463-70. doi: 10.1182/blood-2015-04-585067. Epub 2015 Jun 11.

Initial treatment of CLL: integrating biology and functional status.

Jain N¹, O'Brien S².

Lancet Oncol. 2014 Jan;15(1):48-58. doi: 10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

O'Brien S¹, Furman RR², Coutre SE³, Sharman JP⁴, Burger JA⁵, Blum KA⁶, Grant B⁷, Richards DA⁸, Coleman M², Wierda WG⁵, Jones JA⁶, Zhao W⁹, Heerema NA⁹, Johnson AJ⁶, Izumi R¹⁰, Hamdy A¹⁰, Chang BY¹⁰, Graef T¹⁰, Clow F¹⁰, Buggy JJ¹⁰, James DF¹⁰, Byrd JC⁶.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton

P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.

Leuk Res. 2013 Jul;37(7):747-51. doi: 10.1016/j.leukres.2013.04.011. Epub 2013 May 1.

Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia.

Lebleblian H¹, DeAngelo DJ, Skirvin JA, Stone RM, Wadleigh M, Werner L, Neuberg DS, Bartel S, McDonnell AM.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T¹, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pasutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2391-405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J¹, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

On-line resources that were extremely helpful for reference:

<http://www.cancer.org/cancer/cancercauses/othercarcinogens/infectiousagents/infectiousagentsandcancer/infectious-agents-and-cancer-viruses>

UptoDate.com

Pubmed. <http://www.ncbi.nlm.nih.gov/pubmed>